Running a business today feels like juggling too many balls at once. From managing operations to pleasing customers, the workload can be overwhelming. Many business owners struggle to keep up with ...

As the aggressive growth stock strategist at Zacks Investment Research Brian Bolan usually looks for stocks that have a strong Zacks Style Score for Growth and a weak Zacks Style Score for Value. This ...

Learn more about whether UiPath Inc. or Q2 Holdings, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Redis and UiPath (PATH) expanded their collaboration toward furthering agentic automation solutions for customers. By extending their ...

Learn more about whether UiPath Inc. or Varonis Systems, Inc. is a better investment based on AAII's A+ Investor grades, ...

Fluent Ventures, with $40 million, is backing founders who are replicating proven business models in fintech, health, and ...

UiPath (PATH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Cathie Wood’s ARK ETFs have made a series of trades on Wednesday, April 16th, 2025, with a notable increase in Robinhood Markets Inc (NASDAQ: HOOD) shares and a substantial sell-off of UiPath Inc ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Mizuho lowered the firm’s price target on UiPath (PATH) to $11 from $12 and keeps a Neutral rating on the shares as part of a Q1 preview for ...

Ryan has over 20 years of sales leadership experience, building top-performing teams globally. Before joining Confluent, Ryan led the emerging products division at UiPath, where he oversaw global ...

Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses.